|
|
 |
April 10, 2008 |
Now Available:
Download the podcast of Dr. Heffernan's presentation
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
MSK Video Report:
Dr. Michael P. Heffernan presents "Biologics for Psoriasis: Individualizing Therapy - Who is the Right Patient" from our 5-part series, "Practical Approaches to Solving Psoriasis Challenges"
Arthritis: TMJ in Juvenile Idiopathic Arthritis May Require MRI for Diagnosis, But it Can Heal
TMJ damage in children with JIA can resolve with actual healing of the damaged condyles once the underlying disease is controlled, but MRI might be required to diagnosis the jaw disorder...
Procedures: The Days of Using Potent Anticoagulants to Prevent Pulmonary Embolism After Joint Arthroplasty May Be Numbered
A genome-wide study has identified 7 new genes that appear to increase a person's risk for psoriasis...
Consumer News: Raloxifene Safe for Women With Decreased Kidney Function
The osteoporosis drug raloxifene is safe for women with CKD, effectively promotes bone density, and reduces fractures...
New from PubMed: Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn's Disease
Researchers found that omega-3 free fatty acids were not effective in preventing relapse in patients with Crohn's disease...
BioPharm Business: Amgen Phase III Data Show Denosumab, an Inhibitor of RANK Ligand, Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
Amgen announced results from its study in women with early and late stage postmenopausal osteoporosis that show twice-yearly subcutaneous injections of denosumab increased bone mineral density (BMD) at all sites measured...